The Evolving Role of Targeted Therapies in Melanoma

Source: Targeted Oncology, January 2018

There is an ongoing discussion in the field of metastatic melanoma regarding which treatment should be used first, immunotherapy or targeted therapy, as both are approved for the frontline treatment of these patients. Clinicians currently treating this disease have a variety of treatment options to choose from when they meet with their patients, and several factors need to be considered in order to make an informed decision, explains Hussein A. Tawbi, MD.

In an interview with Targeted Oncology during the Chemotherapy Foundation Symposium, Tawbi, Associate Professor of Melanoma Medical Oncology, and Director of Melanoma Clinical Research at The University of Texas MD Anderson Cancer Center, discussed the considerations he makes when choosing between immunotherapy and targeted therapy and how long-term targeted therapy data can influence treatment decisions.

TARGETED ONCOLOGY: Can you share what you discussed in your talk on targeted therapies in metastatic melanoma?

read the original full article

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories